Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells

Journal of Immune Based Therapies and Vaccines

Volumn 8, Issue , 2010, Pages

  Han, Shuhong ^a   Wang, Yichen ^b   Wang, Bei ^a   Patel, Ekta ^a   Okada, Starlyn ^a   Yang, Li Jun ^c   Moreb, Jan S ^c   Chang, Lung Ji ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Vectorite Biomedica Inc   (Taiwan)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE RECEPTOR CCR6; COMPLEMENTARY DNA; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INHIBITOR OF DIFFERENTIATION 2; INTERLEUKIN 15; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; STEM CELL FACTOR; THROMBOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR PU 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL LINEAGE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PHENOTYPE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; UPREGULATION;

EID: 78549262391     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-8-8     Document Type: Article

References (53)

1. Farkas A, Conrad C, Tonel G, Borbenyi Z, Kemeny L, Dobozy A, Nestle FO. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy. Skin Pharmacol Physiol 2006, 19:124-131. 10.1159/000092592, 16612139.
2. Talarn C, Urbano-Ispizua A, Martino R, Batlle M, Fernandez-Aviles F, Herrera C, Perez-Simon JA, Gaya A, Aymerich M, Petriz J, Marín P, Sierra J, Montserrat E. G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplant 2006, 37:873-879. 10.1038/sj.bmt.1705345, 16547488.
3. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92:4778-4791.
4. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999, 31:323-331. 10.1016/S0168-8278(99)80231-1, 10453947.
5. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001, 98:2992-2998. 10.1182/blood.V98.10.2992, 11698282.
6. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003, 170:3488-3494.
7. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952. 10.1038/nri1498, 15573129.
8. Gervais A, Leveque J, Bouet-Toussaint F, Burtin F, Lesimple T, Sulpice L, Patard JJ, Genetet N, Catros-Quemener V. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res 2005, 7:R326-335. 10.1186/bcr1001, 1143555, 15987427.
9. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008, 19:65-77. 10.1016/j.cytogfr.2007.10.008, 18061513.
10. Wu L, D'Amico A, Hochrein H, O'Keeffe M, Shortman K, Lucas K. Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 2001, 98:3376-3382. 10.1182/blood.V98.12.3376, 11719377.
11. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood 2002, 100:4512-4520. 10.1182/blood-2001-11-0097, 12393628.
12. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161. 10.1038/nri746, 11913066.
13. Chicha L, Jarrossay D, Manz MG. Clonal type I interferon-producing and dendritic cell precursors are contained in both human lymphoid and myeloid progenitor populations. J Exp Med 2004, 200:1519-1524. 10.1084/jem.20040809, 2211954, 15557348.
14. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006, 24:287-320. 10.1146/annurev.immunol.24.021605.090612, 16551251.
15. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661. 10.1126/science.1178331, 20133564.
16. Zenke M, Hieronymus T. Towards an understanding of the transcription factor network of dendritic cell development. Trends Immunol 2006, 27:140-145. 10.1016/j.it.2005.12.007, 16406699.
17. Canque B, Camus S, Dalloul A, Kahn E, Yagello M, Dezutter-Dambuyant C, Schmitt D, Schmitt C, Gluckman JC. Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells. Blood 2000, 96:3748-3756.
18. Hao QL, Zhu J, Price MA, Payne KJ, Barsky LW, Crooks GM. Identification of a novel, human multilymphoid progenitor in cord blood. Blood 2001, 97:3683-3690. 10.1182/blood.V97.12.3683, 11389003.
19. Ferlazzo G, Klein J, Paliard X, Wei WZ, Galy A. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J Immunother 2000, 23:48-58. 10.1097/00002371-200001000-00007, 10687137.
20. Chen X, He J, Chang L-J. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 2004, 1:37. 10.1186/1742-4690-1-37, 534092, 15518595.
21. Curti A, Fogli M, Ratta M, Tura S, Lemoli RM. Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR-dendritic cell precursors. J Immunol 2001, 166:848-854.
22. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996, 184:695-706. 10.1084/jem.184.2.695, 2192705, 8760823.
23. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001, 194:1013-1020. 10.1084/jem.194.7.1013, 2193478, 11581322.
24. Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 2004, 34:66-73. 10.1002/eji.200324567, 14971031.
25. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3:269-279. 10.1038/nri1052, 12669018.
26. Dubois SP, Waldmann TA, Muller JR. Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci USA 2005, 102:8662-8667. 10.1073/pnas.0503360102, 1150852, 15932944.
27. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009, 7:109. 10.1186/1479-5876-7-109, 2807857, 20021667.
28. Hardy MY, Kassianos AJ, Vulink A, Wilkinson R, Jongbloed SL, Hart DN, Radford KJ. NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol Cell Biol 2009, 87:606-614. 10.1038/icb.2009.44, 19546878.
29. Liu A, Takahashi M, Narita M, Zheng Z, Kanazawa N, Abe T, Nikkuni K, Furukawa T, Toba K, Fuse I, Aizawa Y. Generation of functional and mature dendritic cells from cord blood and bone marrow CD34+ cells by two-step culture combined with calcium ionophore treatment. J Immunol Methods 2002, 261:49-63. 10.1016/S0022-1759(01)00545-2, 11861065.
30. Slukvin II, Vodyanik MA, Thomson JA, Gumenyuk ME, Choi KD. Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. J Immunol 2006, 176:2924-2932.
31. Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang L-J. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther 2008, 16:269-279. 10.1038/sj.mt.6300369, 18071334.
32. Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Therapy 1999, 6:715-728. 10.1038/sj.gt.3300895, 10505094.
33. Chang L-J, Zaiss A-K. Self inactivating lentiviral vectors in combination with a sensitive Cre/loxP reporter system. Methods in Molecular Medicine 2001, 367-382. Humana Press Inc, Walker J, Viral Vectors for Gene Therapy: Methods and Protocols.
34. Zaiss A-K, Son S, Chang L-J. RNA 3'-readthrough of oncoretrovirus and lentivirus: implications in vector safety and efficacy. J Virol 2002, 76:7209-7219. 10.1128/JVI.76.14.7209-7219.2002, 136337, 12072520.
35. Wang B, Han S, Lien L, Chang L-J. Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype. Immunology 2009, 128:43-57. 10.1111/j.1365-2567.2009.03067.x, 2747138, 19689735.
36. Han S, Chang LJ. Immunity of lentiviral vector-modified dendritic cells. Methods Mol Biol 2009, 542:245-259. full_text, 19565906.
37. Han S, Huang Y, Liang Y, Ho Y, Wang Y, Chang L-J. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. Journal of Hematology and Oncology 2009, 2:34. 10.1186/1756-8722-2-34, 2729746, 19660111.
38. Wang B, He J, Liu C, Chang L-J. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24:3477-3489. 10.1016/j.vaccine.2006.02.025, 1850619, 16530303.
39. Gammaitoni L, Bruno S, Sanavio F, Gunetti M, Kollet O, Cavalloni G, Falda M, Fagioli F, Lapidot T, Aglietta M, Piacibello W. Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. Exp Hematol 2003, 31:261-270. 10.1016/S0301-472X(02)01077-9, 12644024.
40. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247. 10.1084/jem.20030422, 2194081, 12874257.
41. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006, 108:2655-2661. 10.1182/blood-2006-03-011353, 1895594, 16763205.
42. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, Chaput N, Barrou B, Thioun N, Gattegnio B, Selles F, Six A, Azar N, Lotz JP, Buzyn A, Sibony M, Delcourt A, Boyer O, Herson S, Klatzmann D, Lacave R. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009, 35:569-581. 10.3892/ijo_00000368, 19639177.
43. Luft T, Pang KC, Thomas E, Bradley CJ, Savoia H, Trapani J, Cebon J. A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp Hematol 1998, 26:489-500.
44. Strobl H. Molecular mechanisms of dendritic cell sublineage development from human hematopoietic progenitor/stem cells. Int Arch Allergy Immunol 2003, 131:73-79. 10.1159/000070921, 12811014.
45. Bryder D, Jacobsen SE. Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. Blood 2000, 96:1748-1755.
46. Hutton JF, Rozenkov V, Khor FS, D'Andrea RJ, Lewis ID. Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system. Stem Cells Dev 2006, 15:805-813. 10.1089/scd.2006.15.805, 17253944.
47. Hwang JH, Kim SW, Park SE, Yun HJ, Lee Y, Kim S, Jo DY. Overexpression of stromal cell-derived factor-1 enhances endothelium-supported transmigration, maintenance, and proliferation of hematopoietic progenitor cells. Stem Cells Dev 2006, 15:260-268. 10.1089/scd.2006.15.260, 16646672.
48. Milhem M, Mahmud N, Lavelle D, Araki H, Desimone J, Saunthararajah Y, Hoffman R. Modification of Hematopoietic Stem Cell Fate By 5aza 2'deoxycytidine and Trichostatin A. Blood 2004, 103:4102-4110. 10.1182/blood-2003-07-2431, 14976039.
49. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer. J Immunol 2001, 166:678-689.
50. Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY. IL-4 Prevents the Blockade of Dendritic Cell Differentiation Induced by Tumor Cells. Cancer Res 2001, 61:3096-3104.
51. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 2008, 181:155-164. 2587216, 18566380.
52. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 2002, 169:4928-4935.
53. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004, 101:1969-1974. 10.1073/pnas.0307298101, 357036, 14762166.